BR0114373A - Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante - Google Patents

Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante

Info

Publication number
BR0114373A
BR0114373A BR0114373-5A BR0114373A BR0114373A BR 0114373 A BR0114373 A BR 0114373A BR 0114373 A BR0114373 A BR 0114373A BR 0114373 A BR0114373 A BR 0114373A
Authority
BR
Brazil
Prior art keywords
fvii
vitamin
fviia
host cell
variants
Prior art date
Application number
BR0114373-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Else Marie Nicolaisen
Lars Soegaard Nielsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27439823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0114373(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR0114373A publication Critical patent/BR0114373A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR0114373-5A 2000-10-02 2001-10-02 Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante BR0114373A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200001456 2000-10-02
DKPA200100262 2001-02-16
DKPA200100430 2001-03-14
DKPA200100751 2001-05-14
PCT/DK2001/000635 WO2002029045A2 (en) 2000-10-02 2001-10-02 Method for the production of vitamin k-dependent proteins

Publications (1)

Publication Number Publication Date
BR0114373A true BR0114373A (pt) 2004-02-17

Family

ID=27439823

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0114373-5A BR0114373A (pt) 2000-10-02 2001-10-02 Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
BR0114374-3A BR0114374A (pt) 2000-10-02 2001-10-02 Preparação compreendendo uma pluralidade de polipeptìdeos de fator vii, métodos para a determinação do padrão de glicoforma de fator vii e de polipeptìdeos relacionados com fator vii, e para a produção da dita preparação, formulação farmacêutica, métodos para o tratamento de uma sìndrome responsiva a fator vii, para a prevenção de sangramento indesejado, para a prevenção de coagulação sanguìnea indesejada, e para prevenção de reações mediadas por fator de tecido, e, uso da preparação

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0114374-3A BR0114374A (pt) 2000-10-02 2001-10-02 Preparação compreendendo uma pluralidade de polipeptìdeos de fator vii, métodos para a determinação do padrão de glicoforma de fator vii e de polipeptìdeos relacionados com fator vii, e para a produção da dita preparação, formulação farmacêutica, métodos para o tratamento de uma sìndrome responsiva a fator vii, para a prevenção de sangramento indesejado, para a prevenção de coagulação sanguìnea indesejada, e para prevenção de reações mediadas por fator de tecido, e, uso da preparação

Country Status (18)

Country Link
US (6) US6903069B2 (https=)
EP (6) EP1325113B1 (https=)
JP (4) JP2004512835A (https=)
KR (2) KR100861470B1 (https=)
CN (3) CN1468303B (https=)
AT (2) ATE465253T1 (https=)
AU (5) AU2001291651A1 (https=)
BR (2) BR0114373A (https=)
CA (2) CA2422214A1 (https=)
CZ (1) CZ2003718A3 (https=)
DE (2) DE60141908D1 (https=)
ES (2) ES2344887T3 (https=)
HU (2) HUP0301267A3 (https=)
IL (2) IL154880A0 (https=)
MX (1) MXPA03002853A (https=)
NO (1) NO20031471L (https=)
PL (2) PL361017A1 (https=)
WO (4) WO2002029045A2 (https=)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786070B2 (en) 1997-09-10 2010-08-31 Novo Nordisk Healthcare A/G Subcutaneous administration of coagulation factor VII
US20050032690A1 (en) * 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
NZ507557A (en) 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
CA2739933A1 (en) * 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) * 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
EP1434857B1 (en) 2001-10-02 2007-08-01 Novo Nordisk Health Care AG Method for production of recombinant proteins in eukaryote cells
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
WO2003093465A1 (en) * 2002-04-30 2003-11-13 Maxygen Holdings Ltd. FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
UA86744C2 (en) * 2002-06-21 2009-05-25 Ново Нордиск Хэлс Кеа Аг Pegylated factor vii glycoforms
CN1671410B (zh) * 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
CA2840692A1 (en) * 2002-09-30 2004-04-08 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
AU2004222625A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
CN101818137A (zh) * 2003-03-18 2010-09-01 诺和诺德医疗保健公司 生产含有gla残基的丝氨酸蛋白酶的方法
CA2519873C (en) 2003-03-20 2012-12-18 Maxygen Holdings Ltd. Fvii or fviia variants
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
RU2364609C2 (ru) * 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
RU2373282C2 (ru) 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
EP1641487B1 (en) * 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
CA2529162C (en) * 2003-06-30 2011-03-08 Yasuhiro Kajihara Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
JP5653572B2 (ja) * 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
DE602004025157D1 (de) 2003-09-23 2010-03-04 Univ North Carolina Zellen, die Vitamin-K-Reduktase und Vitamin-K-abhängiges Protein coexprimieren und deren Anwendung zur Verbesserung der Produktivität von diesem Vitamin-K-abhängigen Protein
JP4740138B2 (ja) 2003-10-10 2011-08-03 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 真核生物細胞におけるポリペプチドの大規模生産方法及びそれに適した培養容器
DE602004026897D1 (de) 2003-10-14 2010-06-10 Baxter Healthcare Sa Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
JP4874806B2 (ja) 2003-12-01 2012-02-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 液体因子ｖｉｉ組成物のウイルス濾過
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CN1917861B (zh) * 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
WO2005068620A1 (en) * 2004-01-07 2005-07-28 Novo Nordisk Health Care Ag Method for the production of recombinant proteins
KR20070008645A (ko) 2004-05-04 2007-01-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 폴리펩티드의 ｏ-연결된 단백당형 및 그들의 제조 방법
WO2006018204A1 (en) * 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
US20090043080A1 (en) * 2004-09-29 2009-02-12 Novo Nordisk Healthcare A/G Purification of a Bulk of a Factor VII Polypeptide by Fractionated Elution from an Anion-Exchange Material
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
US20090100533A1 (en) * 2004-12-21 2009-04-16 Novo Nordisk Health Care Ag Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host sytems
EP2360171A1 (en) * 2004-12-23 2011-08-24 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1851305B1 (en) * 2005-02-11 2012-01-18 Novo Nordisk Health Care AG Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
PL1853700T3 (pl) 2005-02-28 2013-05-31 Baxalta Inc Koekspresja przez rekombinowanie podjednostki 1 reduktazy epoksydu witaminy K w celu poprawy ekspresji białka zależnego od witaminy K
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
CN101198696B (zh) * 2005-04-13 2014-02-26 阿斯利康(瑞典)有限公司 包含产生需要γ-羧化的蛋白质用的载体的宿主细胞
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
AU2006331501B2 (en) * 2005-12-21 2013-09-05 Aptevo Biotherapeutics Llc Method of producing biologically active vitamin K dependent proteins by recombinant methods
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US8461115B2 (en) 2006-03-16 2013-06-11 Stellaris Pharmaceuticals Aps Methods for local treatment with factor VII
DE602007007923D1 (de) * 2006-04-11 2010-09-02 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
WO2008009634A2 (en) * 2006-07-17 2008-01-24 Novo Nordisk Health Care Ag Factor viia analogues with increased activity for treating thrombocytopenia
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
WO2008056816A1 (fr) * 2006-11-07 2008-05-15 Kyoto University Support de suspension pour une molécule d'acide nucléique linéaire, procédé d'extension d'une molécule d'acide nucléique linéaire et spécimen de molécule d'acide nucléique linéaire
PT2101821E (pt) * 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
US20100143326A1 (en) * 2007-01-03 2010-06-10 Novo Nordisk Healthcare A/G SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES
HRP20130382T1 (hr) 2007-04-03 2013-05-31 Biogenerix Ag Postupci lijeäśenja pomoä†u glikopegiliranog g-csf
CA2683443A1 (en) * 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypeptides and uses thereof
AU2016238889B2 (en) * 2007-04-26 2019-06-27 Aptevo Biotherapeutics Llc Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
JP6050927B2 (ja) * 2007-04-26 2016-12-21 シーエヌジェイ ホールディングス，インコーポレイテッド 高シアル酸含量を有する組換えビタミンｋ依存性タンパク質およびその調製方法
AU2014202989B2 (en) * 2007-04-26 2016-07-07 Aptevo Biotherapeutics Llc Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
EP2014299A1 (en) * 2007-07-11 2009-01-14 Novo Nordisk A/S Subcutaneous administration of coagulation factor VII
SG187410A1 (en) 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
PT2356247E (pt) 2008-11-12 2015-10-26 Baxalta Inc Método de produção de fator vii isento de soro e de insulina
JP5027106B2 (ja) * 2008-12-25 2012-09-19 一般財団法人阪大微生物病研究会 日本脳炎ウイルス抗原
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
WO2011053738A1 (en) * 2009-10-30 2011-05-05 Inspiration Biopharmaceuticals, Inc. Method of producing recombinant vitamin k dependent proteins
EP2507627A2 (en) * 2009-12-04 2012-10-10 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
FR2954349A1 (fr) 2009-12-22 2011-06-24 Agronomique Inst Nat Rech Sulfatase modifiant selectivement les glycosaminoglycanes
WO2012075138A1 (en) * 2010-11-30 2012-06-07 Progenetics Llc Method of producing biologically active vitamin k dependent proteins in transgenic animals
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2906236A1 (en) 2012-10-10 2015-08-19 Novo Nordisk Health Care AG Liquid pharmaceutical composition of factor vii polypeptide
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
FR3006591B1 (fr) 2013-06-11 2016-05-06 Lab Francais Du Fractionnement Composition de facteur vii presentant un point isoelectrique substantiellement homogene
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
NZ724826A (en) * 2014-04-16 2022-07-29 Cmc Biologics As A high cell density fill and draw fermentation process
AU2015269365A1 (en) 2014-06-04 2016-12-15 Amgen Inc. Methods for harvesting mammalian cell cultures
US9714302B2 (en) 2014-10-10 2017-07-25 W. R. Grace & Co.—Conn. Process for preparing spherical polymerization catalyst components for use in olefin polymerizations
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
AR105669A1 (es) * 2015-08-10 2017-10-25 Glycotope Gmbh Factor vii recombinante mejorado
ES2803773T3 (es) * 2015-12-02 2021-01-29 CSL Behring Lengnau AG Medios mejorados para la expresión de proteínas recombinantes dependientes de vitamina k
EP3488858A1 (en) 2017-11-27 2019-05-29 Laboratoire Français du Fractionnement et des Biotechnologies A von willebrand factor composition for use in treating a pathology mediated by angiogenesis
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
CN117434281B (zh) * 2023-10-18 2026-01-06 上海太阳生物技术有限公司 组合物、检测试剂、检测试剂盒以及在制备检测凝血因子x活性中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189534A (en) * 1976-11-11 1980-02-19 Massachusetts Institute Of Technology Cell culture microcarriers
US4357422A (en) * 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
US4335215A (en) * 1980-08-27 1982-06-15 Monsanto Company Method of growing anchorage-dependent cells
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4664912A (en) * 1984-10-01 1987-05-12 Wiktor Tadeusz J Process for the large scale production of rabies vaccine
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
SE464816B (sv) * 1985-10-15 1991-06-17 Nilsson Kjell Makroporoesa partiklar, foerfarande foer dess framstaellning och dess anvaendning
US4783940A (en) 1985-12-28 1988-11-15 Shimizu Construction Co., Ltd. Concrete filled steel tube column and method of constructing same
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5576194A (en) * 1986-07-11 1996-11-19 Bayer Corporation Recombinant protein production
AU8339187A (en) 1986-11-17 1988-06-16 New England Medical Center Hospitals, Inc., The Enhancing gamma-carboxylation of recombinant vitamin k-dependent proteins
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
AU8427091A (en) * 1990-07-23 1992-02-18 Zymogenetics Inc. Gamma-carboxylase and methods of use
ATE158816T1 (de) * 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
WO1992015686A1 (en) 1991-02-28 1992-09-17 Zymogenetics, Inc. Modified factor vii
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
IL104385A (en) * 1992-01-17 1995-12-31 Applied Research Systems Method and device for growing biomass particles
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
JPH08508875A (ja) * 1992-05-01 1996-09-24 帝人株式会社 蛋白分泌細胞の流加回分培養法
DE4221863C2 (de) 1992-07-03 1997-04-17 Stockhausen Chem Fab Gmbh Copolymere der Allyliminodiessigsäure mit ungesättigten Carbonsäuren und deren Verwendung als Komplexbildner, Peroxidstabilisatoren, Builder in Wasch- und Reinigungsmitteln und Dispergatoren
US5510328A (en) * 1994-04-28 1996-04-23 La Jolla Cancer Research Foundation Compositions that inhibit wound contraction and methods of using same
WO1998004680A1 (en) * 1996-07-26 1998-02-05 University Of Manitoba Serum-free medium for growth of anchorage-dependant mammalian cells
DE59800935D1 (en) * 1997-04-08 2001-08-02 Baxter Ag Immuntolerante prothrombinkomplex-präparation
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
ES2315022T3 (es) * 1998-11-06 2009-03-16 Novo Nordisk Health Care Ag Metodo para la produccion de fvii.
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
DK1200561T3 (da) * 1999-08-05 2006-10-16 Baxter Ag Rekombinant stabil celleklon, dens fremstilling og anvendelse
UA74557C2 (en) * 1999-09-03 2006-01-16 Applied Research Systems A method for producing a heterologous secreted protein from chinese hamster ovaries cells grown on microcarriers
NZ522215A (en) * 2000-04-26 2004-05-28 Aventis Pharma Gmbh EDG8 receptor, its preparation and use

Also Published As

Publication number Publication date
IL154879A0 (en) 2003-10-31
US20020137673A1 (en) 2002-09-26
IL154880A0 (en) 2003-10-31
US20090281022A1 (en) 2009-11-12
AU2001295431A1 (en) 2002-04-15
HUP0301245A2 (hu) 2003-09-29
EP1325127A2 (en) 2003-07-09
AU9165201A (en) 2002-04-15
ES2323761T3 (es) 2009-07-24
JP2004510436A (ja) 2004-04-08
CZ2003718A3 (cs) 2003-08-13
EP1325127B1 (en) 2009-03-11
WO2002029045A2 (en) 2002-04-11
HUP0301267A3 (en) 2005-12-28
WO2002029025A3 (en) 2002-10-10
PL361017A1 (en) 2004-09-20
JP2004510439A (ja) 2004-04-08
EP1325113B1 (en) 2010-04-21
MXPA03002853A (es) 2005-05-16
US20050075289A1 (en) 2005-04-07
AU2001291652B2 (en) 2007-09-13
CA2422216C (en) 2010-03-16
JP2004510786A (ja) 2004-04-08
AU2001291651A1 (en) 2002-04-15
WO2002029025A2 (en) 2002-04-11
EP2261330A1 (en) 2010-12-15
ES2344887T3 (es) 2010-09-09
DE60137950D1 (de) 2009-04-23
DE60141908D1 (de) 2010-06-02
CN1468303A (zh) 2004-01-14
JP4477299B2 (ja) 2010-06-09
CA2422216A1 (en) 2002-04-11
EP2311943A3 (en) 2011-05-04
US20040058413A1 (en) 2004-03-25
ATE425254T1 (de) 2009-03-15
JP4361730B2 (ja) 2009-11-11
NO20031471D0 (no) 2003-04-01
NO20031471L (no) 2003-05-30
EP1325147A2 (en) 2003-07-09
HUP0301245A3 (en) 2005-12-28
CN102766668B (zh) 2016-03-16
AU2001291653A1 (en) 2002-04-15
WO2002029025A9 (en) 2003-05-15
EP1356074A2 (en) 2003-10-29
EP1325113A2 (en) 2003-07-09
PL361058A1 (en) 2004-09-20
US20020151471A1 (en) 2002-10-17
HUP0301267A2 (hu) 2003-09-29
ATE465253T1 (de) 2010-05-15
US20070122884A1 (en) 2007-05-31
WO2002029084A3 (en) 2002-09-26
WO2002029045A3 (en) 2002-10-10
US8202973B2 (en) 2012-06-19
CN1468303B (zh) 2012-07-18
WO2002029084A2 (en) 2002-04-11
WO2002029083A2 (en) 2002-04-11
CA2422214A1 (en) 2002-04-11
KR20030034245A (ko) 2003-05-01
EP2311943A2 (en) 2011-04-20
KR100880624B1 (ko) 2009-01-30
WO2002029083A3 (en) 2003-08-21
US6903069B2 (en) 2005-06-07
CN1481438A (zh) 2004-03-10
JP2004512835A (ja) 2004-04-30
KR100861470B1 (ko) 2008-10-02
KR20030081310A (ko) 2003-10-17
CN102766668A (zh) 2012-11-07
BR0114374A (pt) 2003-12-30

Similar Documents

Publication Publication Date Title
BR0114373A (pt) Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
Zhong et al. The prosegments of furin and PC7 as potent inhibitors of proprotein convertases: in vitro and ex vivo assessment of their efficacy and selectivity
McGuire et al. Purification and characterization of a high molecular weight proteinase (macropain) from human erythrocytes
Gao et al. Activation of the proteolytic activity of ADAMTS4 (aggrecanase-1) by C-terminal truncation
BR0214653A (pt) Polipeptìdeo, sequência de ácido nucleico isolada, construção de ácido nucleìco, vetor de expressão recombinante, célula hospedeira recombinante, método para produzir um polipeptìdeo, cepa, uso de pelo menos uma protease, método para melhorar o valor nutricional de uma ração animal, aditivo para ração animal, composição de ração animal, e, método para o tratamento de proteìnas vegetais
ATE500323T1 (de) Subtilisin-variante
Huang et al. Proteolysis of platelet cortactin by calpain
EP2108046B9 (en) Fviii-independent fix-mutant proteins for hemophilia a treatment
KR102500777B1 (ko) 우유-응고 특성이 개선된 키모신 변이체
MXPA06001173A (es) Metodo analitico para la pancreatina y composiciones comparables.
Nakamura et al. Contribution of calpain Lp82–induced proteolysis to experimental cataractogenesis in mice
BR0009393A (pt) Polipeptìdeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, método para a produção do polipeptìdeo, uso de um polipeptìdeo, e, composição detergente
Marie-Claire et al. Intramolecular processing of prothermolysin
EP1129179A4 (en) UDP-galactose: BETA-I (N) -acetyl-glucosamine BETA1,3 galactosyltransferases, BETA3Gal-T5
Renatus et al. Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage
Andrade et al. Purification and characterization of angiotensin I-converting enzymes from mesangial cells in culture
DK1209985T3 (da) Modification af proteiners skumningsegenskaber
DE60025467D1 (de) Oxalacetat-hydrolase defiziente fungale wirtszellen
ATE307205T1 (de) Gefrorenes lebensmittel
Zou et al. ADAM33 enzyme properties and substrate specificity
Berman et al. Purification and Characterization of a Dynorphin-processing Endopeptidase (∗)
Tomkinson et al. Structure-function studies of recombinant murine tripeptidyl-peptidase II: the extra domain which is subject to alternative splicing is involved in complex formation
Seetharam et al. Cloning and expression of rat coagulation factor VII
Vatandoost et al. The effects of influencing factors on γ-carboxylation and expression of recombinant vitamin K dependent coagulation factors
Seol et al. The 65-kDa protein derived from the internal translational start site of the clpA gene blocks autodegradation of ClpA by the ATP-dependent protease Ti in Escherichia coli

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NOVO NORDISK HEALTH CARE AG (CH)

Free format text: TRANSFERIDO DE: NOVO NORDISK A/S

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.